Abstract

Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Keir, H., Long, M., Abo leyah, H., Giam, Y., Vadiveloo, T., Pembridge, T., Hull, R., Delgado, L., Band, M., McLaren-Neil, F., Adamson, S., Lahnsteiner, E., Gilmour, A., Hughes, C., New, B., Connell, D., Dowey, R., Turton, H., Richardson, H., Cassidy, D., Cooper, J., Suntharalingam, J., Diwakar, L., Russell, P., Underwood, J., Hicks, A., Dosanjh, D., Sage, E., Dhasmana, D., Spears, M., Thompson, R., Brightling, C., Patel, M., George, J., Condliffe, A., Shoemark, A., Maclennan, G. & Chalmers, J. 2022, 'A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial', American Thoracic Society International Conference 2022. https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 23 November 2023
Was this page helpful?